Anti-Human HLA-DRA Recombinant Antibody (1D09C3), FITC (HM812117)

Name: Anti-Human HLA-DRA Recombinant Antibody (1D09C3), FITC
Brand: abinScience
SKU: HM812117
Price: 118 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50T
100T

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HM812117
Reactivité des espèces	Human
Applications	FCM
Espèce hôte	Mouse
Clonalité	Monoclonal
Isotype	IgG1, kappa
ID de clone	1D09C3
Conjugaison	FITC
Cible	HLA-DRA1, MHC class II antigen DRA, HLA-DRA, HLA class II histocompatibility antigen, DR alpha chain
Niveau d'endotoxines	Please contact with the lab for this information.
Produits associés	Mouse IgG1, kappa Recombinant Isotype Control Antibody (MOPC-21), FITC
Numéro d'accès	P01903
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Store at 4°C for 12 months. Protect from light. Do not freeze.
Contexte	HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) is a ~28 kDa protein. An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. 1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931 2. Röhn, TA. et al. (2004) Nature immunology 5, 909-18. PMID: 15322540 3. Deng, L. et al. (2007) Nature immunology 8, 398-408. PMID: 17334368 4. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072 5. Scally, SW. et al. (2013) The Journal of experimental medicine 210, 2569-82. PMID: 24190431 6. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323 7. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618 8. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665 9. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819 10. Kropshofer, H. et al. (1997) Immunity 6, 293-302. PMID: 9075930
Note	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.

Images

Flow Cytometry

Flow-cytometry using FITC anti-human HLA-DRA antibody. Daudi cells were stained with an irrelevant antibody (Green Histogram) or a FITC anti-human HLA-DRA antibody monoclonal antibody (Catalog # HM812117, Red Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

Reférences

Fiche technique